British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.